SCHEMBL7334154

SCHEMBL7334154

NN=Cc1ccc2cc(C(=O)Nc3ccc(Br)cn3)ccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.67
NPC1 O15118 10/20 0.67
KMT2A Q03164 5/20 0.67
MEN1 O00255 4/20 0.67
RXFP1 Q9HBX9 2/20 0.56
DEGS1 O15121 1/20 0.49
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 1/20 0.44
MTOR P42345 1/20 0.43
ALDH1A1 P00352 2/20 0.42
POLB P06746 2/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 1/20 0.42
MAPK1 P28482 1/20 0.42
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7334320 0.86 KDM4E (0.52) RAB9ANPC1KMT2AMEN1RXFP1
SCHEMBL7346861 0.81 SIRT2 (0.53) RAB9ANPC1KMT2AMEN1DEGS1
SCHEMBL7334144 0.80 NPC1 (0.74) RAB9ANPC1KMT2AMEN1RXFP1
SCHEMBL7401550 0.79 CSNK2A2 (0.42) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL7337895 0.77 DNM1 (0.38) RAB9ANPC1KMT2AMEN1DEGS1
SCHEMBL7346207 0.76 BCAT2 (0.47) RAB9ANPC1DEGS1KDM4EKLK1
SCHEMBL7341819 0.76 SIRT2 (0.54) RAB9ANPC1KMT2AMEN1DEGS1
SCHEMBL7340325 0.76 GRM5 (0.56) RAB9ANPC1SMN1; SMN2MAPTTP53
SCHEMBL7406451 0.76 RAB9A (0.56) RAB9ANPC1KMT2AMEN1RXFP1
SCHEMBL1971692 0.74 NPC1 (0.69) RAB9ANPC1KMT2AMEN1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 RAB9A 2845/4885NPC1 2478/4885KMT2A 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.